GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TG Therapeutics Inc (NAS:TGTX) » Definitions » Cyclically Adjusted Book per Share

TG Therapeutics (TG Therapeutics) Cyclically Adjusted Book per Share : $1.52 (As of Mar. 2024)


View and export this data going back to 1995. Start your Free Trial

What is TG Therapeutics Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

TG Therapeutics's adjusted book value per share for the three months ended in Mar. 2024 was $1.036. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $1.52 for the trailing ten years ended in Mar. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of TG Therapeutics was 74.20% per year. The lowest was -63.80% per year. And the median was -39.20% per year.

As of today (2024-05-19), TG Therapeutics's current stock price is $16.48. TG Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $1.52. TG Therapeutics's Cyclically Adjusted PB Ratio of today is 10.84.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of TG Therapeutics was 30.56. The lowest was 0.03. And the median was 3.87.


TG Therapeutics Cyclically Adjusted Book per Share Historical Data

The historical data trend for TG Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TG Therapeutics Cyclically Adjusted Book per Share Chart

TG Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -18.20 -1.04 1.46 1.51 1.51

TG Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.52 1.53 1.53 1.51 1.52

Competitive Comparison of TG Therapeutics's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, TG Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TG Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TG Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where TG Therapeutics's Cyclically Adjusted PB Ratio falls into.



TG Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, TG Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.036/131.7762*131.7762
=1.036

Current CPI (Mar. 2024) = 131.7762.

TG Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201406 1.367 100.560 1.791
201409 1.619 100.428 2.124
201412 1.783 99.070 2.372
201503 2.240 99.621 2.963
201506 2.187 100.684 2.862
201509 2.215 100.392 2.907
201512 1.879 99.792 2.481
201603 1.654 100.470 2.169
201606 1.445 101.688 1.873
201609 1.037 101.861 1.342
201612 0.632 101.863 0.818
201703 1.513 102.862 1.938
201706 1.145 103.349 1.460
201709 1.126 104.136 1.425
201712 0.916 104.011 1.161
201803 1.106 105.290 1.384
201806 1.229 106.317 1.523
201809 0.865 106.507 1.070
201812 0.287 105.998 0.357
201903 0.217 107.251 0.267
201906 0.141 108.070 0.172
201909 -0.267 108.329 -0.325
201912 0.353 108.420 0.429
202003 -0.012 108.902 -0.015
202006 1.534 108.767 1.859
202009 1.324 109.815 1.589
202012 3.694 109.897 4.429
202103 3.147 111.754 3.711
202106 2.682 114.631 3.083
202109 2.179 115.734 2.481
202112 1.656 117.630 1.855
202203 1.179 121.301 1.281
202206 0.889 125.017 0.937
202209 0.691 125.227 0.727
202212 0.400 125.222 0.421
202303 0.184 127.348 0.190
202306 0.268 128.729 0.274
202309 1.088 129.860 1.104
202312 1.060 129.419 1.079
202403 1.036 131.776 1.036

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


TG Therapeutics  (NAS:TGTX) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

TG Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=16.48/1.52
=10.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of TG Therapeutics was 30.56. The lowest was 0.03. And the median was 3.87.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


TG Therapeutics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of TG Therapeutics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


TG Therapeutics (TG Therapeutics) Business Description

Industry
Traded in Other Exchanges
Address
3020 Carrington Mill boulevard, Suite 475, Morrisville, NC, USA, 27560
TG Therapeutics Inc is a fully-integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.
Executives
Laurence N Charney director MARVEL ENTERTAINMENT, INC., 417 FIFTH AVENUE, NEW YORK NY 10016
Sean A Power officer: CFO, Secretary and Treasurer 787 SEVENTH AVENUE, 48TH FLOOR, NEW YORK NY 10019
Michael S Weiss director, officer: CEO and President 750 LEXINGTON AVE, NEW YORK NY 10022
Sagar Lonial director C/O TG THERAPEUTICS, INC., 2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK NY 10014
Yann Echelard director C/O LFB BIOTECHNOLOGIES, S.A.S., 3, AVENUE DES TROPIQUES LES ULIS, COURTABOEUF I0 91958
Ra Capital Management, L.p. 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Kenneth Hoberman director 750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10024
Daniel Hume director 3 COLUMBUS CIRCLE, 15TH FLOOR, NEW YORK NY 10019
William James Kennedy director C/O XTL BIOPHARMACEUTICALS LTD, 711 EXECUTIVE BLVD., SUITE Q, VALLEY COTTAGE NY 10989
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Rajeev M. Shah 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Lfb Biotechnologies S.a.s.u. 10 percent owner 3 AVENUE DES TROPIQUES, LES ULIS, COURTABOEUF I0 91958
Mark Schoenebaum director 787 SEVENTH AVENUE, 48TH FLOOR, NEW YORK NY 10019
Opus Point Partners, Llc 10 percent owner 787 7TH AVENUE, 48TH FLOOR, NEW YORK NY 10019

TG Therapeutics (TG Therapeutics) Headlines

From GuruFocus